Amdocal plus 50 10pcs

Description
Amdocal Plus consists of Amlodipine Besylate and Atenolol. Amlodipine
Besylate is a dihydropyridine calcium antagonist that inhibits the
transmembrane influx of calcium ions into vascular smooth muscle and
cardiac muscle. The contractile processes of cardiac muscle and vascular
smooth muscle are dependent upon the movement of extracellular
calcium ions into these cells through specific ion channels. Amlodipine
inhibits calcium ion influx across cell membranes selectively, with a
greater effect on vascular smooth muscle cells than on cardiac muscle
cells. Amlodipine acts directly on vessels to cause a reduction in peripheral
vascular resistance and reduction in blood pressure. Atenolol is (2-
hydroxy-3-isopropyl-aminopropoxy) phenylacetamide, a selective b1
blocker. Beta blockers are the b adrenoceptor blocking drugs, blocking
the effects of adrenergic stimulation mediated through these receptors. It
is devoid of intrinsic sympathomimetic activity and it decreases heart rate
and cardiac output. Further, Atenolol decreases plasma renin activity.

Indications

• Hypertension not controlled by monotherapy
• Angina pectoris & hypertension co-existing diseases
• Post MI patients
• Refractory angina pectoris where nitrate therapy has failed

Dosage and Administration

The recommended dosage is one tablet daily of Amdocal Plus 50
(Amlodipine 5 mg + Atenolol 50 mg) or Amdocal Plus 25 (Amlodipine
5 mg + Atenolol 25 mg). Depending upon the therapeutic response,
titration of the dosage is recommended. In elderly patients, it is advisable
to initiate the therapy with 1/2 tablet of fixed dose combination of
Amlodipine & Atenolol (i.e. 2.5 mg of Amlodipine & 25 mg Atenolol).

Side Effects
Amlodipine : Peripheral oedema may occasionally be present but is fully
reversible. As with other calcium channel blockers peripheral oedema and
skin erythema occur in a proportion of patients and facial flushing occurs
in 2-5% of patients. Complaints of fatigue were also reported more
frequently than in placebo-treated patients. There is evidence that these
effects are more common in patients treated with doses greater than 10
mg daily.
Atenolol : Pronounced fatigue and cold extremities have been observed in
10 to 20% of the treated subjects. Complaints of bradycardia, dizziness
and gastrointestinal symptoms are less frequent. Despite its relative
selectivity, Atenolol can cause bronchospasms in asthma patients. Rarely
observed side effects are sleep disturbances, depressions, paraesthesia,
impotence, exanthema, psoriasis exacerbations and arthropathies.
Clinically relevant changes in the blood sugar have hardly occurred.